



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,915	01/18/2002	Jennifer Hillman	PF-0722 USN	1605
27904	7590	12/12/2003		
INCYTE CORPORATION (formerly known as Incyte Genomics, Inc.) 3160 PORTER DRIVE PALO ALTO, CA 94304			EXAMINER CARLSON, KAREN C	
			ART UNIT	PAPER NUMBER
			1653	

DATE MAILED: 12/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

## Application No.

10/031,915

## Applicant(s)

HILLMAN ET AL.

## Examiner

Karen Cochrane Carlson, Ph.D.

## Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-192 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-192 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
- a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

Art Unit: 1653

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1, 2, 16, 17, and 30, drawn to polypeptide having SEQ ID NO: 1.  
Group 2, claim(s) 1, 2, 16, 17, and 31, drawn to polypeptide having SEQ ID NO: 2.  
Group 3, claim(s) 1, 2, 16, 17, and 32, drawn to polypeptide having SEQ ID NO: 3.  
Group 4, claim(s) 1, 2, 16, 17, and 33, drawn to polypeptide having SEQ ID NO: 4.  
Group 5, claim(s) 1, 2, 16, 17, and 34, drawn to polypeptide having SEQ ID NO: 5.  
Group 6, claim(s) 1, 2, 16, 17, and 35, drawn to polypeptide having SEQ ID NO: 6.  
Group 7, claim(s) 1, 2, 16, 17, and 36, drawn to polypeptide having SEQ ID NO: 7.  
Group 8, claim(s) 1, 2, 16, 17, and 37, drawn to polypeptide having SEQ ID NO: 10.  
Group 9, claim(s) 1, 2, 16, 17, and 38, drawn to polypeptide having SEQ ID NO: 11.  
Group 10, claim(s) 1, 2, 16, 17, and 39, drawn to polypeptide having SEQ ID NO: 12.  
Group 11, claim(s) 1, 2, 16, 17, and 40, drawn to polypeptide having SEQ ID NO: 13.  
Group 12, claim(s) 1, 2, 16, 17, and 41, drawn to polypeptide having SEQ ID NO: 14.  
Group 13, claim(s) 1, 2, 16, 17, and 42, drawn to polypeptide having SEQ ID NO: 15.  
Group 14, claim(s) 1, 2, 16, 17, and 43, drawn to polypeptide having SEQ ID NO: 17.  
Group 15, claim(s) 1, 2, 16, 17, and 44, drawn to polypeptide having SEQ ID NO: 18.  
Group 16, claim(s) 1, 2, 16, 17, and 45, drawn to polypeptide having SEQ ID NO: 20.  
Group 17, claim(s) 1, 2, 16, 17, and 46, drawn to polypeptide having SEQ ID NO: 22.  
Group 18, claim(s) 1, 2, 16, 17, and 47, drawn to polypeptide having SEQ ID NO: 23.  
Group 19, claim(s) 1, 2, 16, 17, and 48, drawn to polypeptide having SEQ ID NO: 24.  
Group 20, claim(s) 1, 2, 16, 17, and 49, drawn to polypeptide having SEQ ID NO: 25.  
Group 21, claim(s) 1, 2, 16, 17, and 50, drawn to polypeptide having SEQ ID NO: 26.  
Group 22, claim(s) 1, 2, 16, 17, and 51, drawn to polypeptide having SEQ ID NO: 28.  
Group 23, claim(s) 1, 2, 16, 17, and 52, drawn to polypeptide having SEQ ID NO: 29.  
Group 24, claim(s) 1, 2, 16, 17, and 53, drawn to polypeptide having SEQ ID NO: 30.  
Group 25, claim(s) 1, 2, 16, 17, and 54, drawn to polypeptide having SEQ ID NO: 31.  
Group 26, claim(s) 1, 2, 16, 17, and 55, drawn to polypeptide having SEQ ID NO: 32.  
Group 27, claim(s) 1, 2, 16, 17, and 56, drawn to polypeptide having SEQ ID NO: 33.  
Group 28 claim(s) 1, 2, 16, 17, and 57, drawn to polypeptide having SEQ ID NO: 34.  
Group 29, claim(s) 1, 2, 16, 17, and 58, drawn to polypeptide having SEQ ID NO: 35.  
Group 30, claim(s) 1, 2, 16, 17, and 59, drawn to polypeptide having SEQ ID NO: 36.  
Group 31, claim(s) 1, 2, 16, 17, and 60, drawn to polypeptide having SEQ ID NO: 37.  
Group 32, claim(s) 1, 2, 16, 17, and 61, drawn to polypeptide having SEQ ID NO: 38.  
Group 33, claim(s) 1, 2, 16, 17, and 62, drawn to polypeptide having SEQ ID NO: 39.  
Group 34, claim(s) 1, 2, 16, 17, and 63, drawn to polypeptide having SEQ ID NO: 41.  
Group 35, claim(s) 1, 2, 16, 17, and 64, drawn to polypeptide having SEQ ID NO: 42.  
Group 36, claim(s) 1, 2, 16, 17, and 65, drawn to polypeptide having SEQ ID NO: 43.  
Group 37, claim(s) 1, 2, 16, 17, and 66, drawn to polypeptide having SEQ ID NO: 44.  
Group 38, claim(s) 1, 2, 16, 17, and 67, drawn to polypeptide having SEQ ID NO: 45.  
Group 39, claim(s) 1, 2, 16, 17, and 68, drawn to polypeptide having SEQ ID NO: 46.  
Group 40, claim(s) 1, 2, 16, 17, and 69, drawn to polypeptide having SEQ ID NO: 47.

Art Unit: 1653

Group 41, claim(s) 1, 2, 16, 17, and 70, drawn to polypeptide having SEQ ID NO: 48.  
Group 42, claim(s) 1, 2, 16, 17, and 71, drawn to polypeptide having SEQ ID NO: 50.  
Group 43, claim(s) 1, 2, 16, 17, and 72, drawn to polypeptide having SEQ ID NO: 51.  
Group 44, claim(s) 1, 2, 16, 17, and 73, drawn to polypeptide having SEQ ID NO: 52.  
Group 45, claim(s) 1, 2, 16, 17, and 74, drawn to polypeptide having SEQ ID NO: 53.  
Group 46, claim(s) 1, 2, 16, 17, and 75, drawn to polypeptide having SEQ ID NO: 54.

Group 47, claim(s) 3-7, 9, 11, 12, 184-192, 76, and 122, drawn to a polynucleotide encoding polypeptide having SEQ ID NO: 1.  
Group 47, claim(s) 3-7, 9, 11, 12, 184-192, 77, and 123, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 2.  
Group 49, claim(s) 3-7, 9, 11, 12, 184-192, 78 and 124, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 3.  
Group 50, claim(s) 3-7, 9, 11, 12, 184-192, 79, and 125, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 4.  
Group 51, claim(s) 3-7, 9, 11, 12, 184-192, 80, and 126, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 5.  
Group 52, claim(s) 3-7, 9, 11, 12, 184-192, 81, and 127, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 6.  
Group 53, claim(s) 3-7, 9, 11, 12, 184-192, 82, and 128, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 7.  
Group 54, claim(s) 3-7, 9, 11, 12, 184-192, 83, and 129, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 10.  
Group 55, claim(s) 3-7, 9, 11, 12, 184-192, 84, and 130, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 11.  
Group 56, claim(s) 3-7, 9, 11, 12, 184-192, 85, and 131, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 12.  
Group 57, claim(s) 3-7, 9, 11, 12, 184-192, 86, and 132, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 13.  
Group 58, claim(s) 3-7, 9, 11, 12, 184-192, 87, and 133, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 14.  
Group 59, claim(s) 3-7, 9, 11, 12, 184-192, 88, and 134, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 15.  
Group 60, claim(s) 3-7, 9, 11, 12, 184-192, 89, and 135, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 17.  
Group 61, claim(s) 3-7, 9, 11, 12, 184-192, 90, and 136, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 18.  
Group 62, claim(s) 3-7, 9, 11, 12, 184-192, 91, and 137, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 20.  
Group 63, claim(s) 3-7, 9, 11, 12, 184-192, 92, and 138, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 22.  
Group 64, claim(s) 3-7, 9, 11, 12, 184-192, 93, and 139, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 23.  
Group 65, claim(s) 3-7, 9, 11, 12, 184-192, 94, and 140, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 24.  
Group 66, claim(s) 3-7, 9, 11, 12, 184-192, 95, and 141, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 25.  
Group 67, claim(s) 3-7, 9, 11, 12, 184-192, 96, and 142, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 26

Art Unit: 1653

Group 68, claim(s) 3-7, 9, 11, 12, 184-192, 97, and 143, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 28.

Group 69, claim(s) 3-7, 9, 11, 12, 184-192, 98, and 144, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 29.

Group 70, claim(s) 3-7, 9, 11, 12, 184-192, 99, and 145, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 30.

Group 71, claim(s) 3-7, 9, 11, 12, 184-192, 100, and 146, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 31.

Group 72, claim(s) 3-7, 9, 11, 12, 184-192, 101, and 147, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 32.

Group 73, claim(s) 3-7, 9, 11, 12, 184-192, 102, and 148, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 33.

Group 74, claim(s) 3-7, 9, 11, 12, 184-192, 103, and 149, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 34.

Group 75, claim(s) 3-7, 9, 11, 12, 184-192, 104, and 150, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 35.

Group 76, claim(s) 3-7, 9, 11, 12, 184-192, 105, and 151, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 36.

Group 77, claim(s) 3-7, 9, 11, 12, 184-192, 106, and 152, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 37.

Group 78, claim(s) 3-7, 9, 11, 12, 184-192, 107, and 153, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 38.

Group 79, claim(s) 3-7, 9, 11, 12, 184-192, 108, and 154, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 39.

Group 80, claim(s) 3-7, 9, 11, 12, 184-192, 109, and 155, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 41.

Group 81, claim(s) 3-7, 9, 11, 12, 184-192, 110, and 156, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 42.

Group 82, claim(s) 3-7, 9, 11, 12, 184-192, 111, and 157, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 43.

Group 83, claim(s) 3-7, 9, 11, 12, 184-192, 112, and 158, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 44.

Group 84, claim(s) 3-7, 9, 11, 12, 184-192, 113, and 159, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 45.

Group 85, claim(s) 3-7, 9, 11, 12, 184-192, 114, and 160, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 46.

Group 86, claim(s) 3-7, 9, 11, 12, 184-192, 115, and 161, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 47.

Group 87, claim(s) 3-7, 9, 11, 12, 184-192, 116, and 162, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 48.

Group 88, claim(s) 3-7, 9, 11, 12, 184-192, 117, and 163, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 50.

Group 89, claim(s) 3-7, 9, 11, 12, 184-192, 118, and 164, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 51.

Group 90, claim(s) 3-7, 9, 11, 12, 184-192, 119, and 165, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 52.

Group 91, claim(s) 3-7, 9, 11, 12, 184-192, 120, and 166, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 53.

Group 92, claim(s) 3-7, 9, 11, 12, 184-192, 121, and 167, drawn to polynucleotide encoding polypeptide having SEQ ID NO: 54.

Art Unit: 1653

Group 93, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 1.  
Group 94, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 2.  
Group 95, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 3.  
Group 96, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 4.  
Group 97, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 5.  
Group 98, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 6.  
Group 99, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 7.  
Group 100, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 10.  
Group 101, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 11.  
Group 102, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 12.  
Group 103, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 13.  
Group 104, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 14.  
Group 105, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 15.  
Group 106, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 17.  
Group 107, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 18.  
Group 108, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 20.  
Group 109, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 22.  
Group 110, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 23.  
Group 111, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 24.  
Group 112, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 25.  
Group 113, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 26.  
Group 114, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 28.  
Group 115, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 29.  
Group 116, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 30.

Art Unit: 1653

Group 117, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 31.

Group 118, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 32.

Group 119, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 33.

Group 120, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 34.

Group 121, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 35.

Group 122, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 36.

Group 123, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 37.

Group 124, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 38.

Group 125, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 39.

Group 126, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 41.

Group 127, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 42.

Group 128, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 43.

Group 129, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 44.

Group 130, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 45.

Group 131, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 46.

Group 132, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 47.

Group 133, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 48.

Group 134, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 50.

Group 135, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 51.

Group 136, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 52.

Group 137, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 53.

Group 138, claim(s) 8, drawn to transgenic organism comprising polynucleotide encoding polypeptide having SEQ ID NO: 54.

Group 139, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 1.

Group 140, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 2.

Art Unit: 1653

Group 141, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 3.  
Group 142, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 4.  
Group 143, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 5.  
Group 144, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 6.  
Group 145, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 7.  
Group 146, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 10.  
Group 147, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 11.  
Group 148, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 12.  
Group 149, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 13.  
Group 150, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 14.  
Group 151, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 15.  
Group 152, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 17.  
Group 153, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 18.  
Group 154, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 20.  
Group 155, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 22.  
Group 156, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 23.  
Group 157, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 24.  
Group 158, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 25.  
Group 159, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 26.  
Group 160, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 28.  
Group 161, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 29.  
Group 162, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 30.  
Group 163, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 31.  
Group 164 claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 32.  
Group 165, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 33.



Art Unit: 1653

Group 166, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 34.

Group 167, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 35.

Group 168, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 36.

Group 169, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 37.

Group 170, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 38.

Group 171, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 39.

Group 172, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 41.

Group 173, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 42.

Group 174 claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 43.

Group 175, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 44.

Group 176, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 45.

Group 177, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 46.

Group 178, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 47.

Group 179, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 48.

Group 180, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 50.

Group 181, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 51.

Group 182 claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 52.

Group 183, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 53.

Group 184, claim(s) 10 and 168-183, drawn to antibody against polypeptide having SEQ ID NO: 54.

Group 185, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 1.

Group 186, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 2.

Group 187, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 3.

Group 188, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 4.

Group 189, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 5.



Art Unit: 1653

Group 215, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 37.

Group 216, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 38.

Group 217, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 39.

Group 218, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 41.

Group 219, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 42.

Group 220, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 43.

Group 221, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 44.

Group 222, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 45.

Group 223, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 46.

Group 224, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 47.

Group 225, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 48.

Group 226, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 50.

Group 227, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 51.

Group 228, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 52.

Group 229, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 53.

Group 230, claim(s) 13-15, drawn to method for detecting polynucleotide using polynucleotide encoding polypeptide having SEQ ID NO: 54.

Group 231, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 1.

Group 232, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 2.

Group 233, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 3.

Group 234, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 4.

Group 235, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 5.

Group 236, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 6.

Group 237, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 7.

Art Unit: 1653

Group 238, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 10.  
Group 239, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 11.  
Group 240, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 12.  
Group 241, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 13.  
Group 242, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 14.  
Group 243, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 15.  
Group 244, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 17.  
Group 245, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 18.  
Group 246, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 20.  
Group 247, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 22.  
Group 248, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 23.  
Group 249, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 24.  
Group 250, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 25.  
Group 251, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 26.  
Group 252, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 28.  
Group 253, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 29.  
Group 254, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 30.  
Group 255, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 31.  
Group 256, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 32.  
Group 257, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 33.  
Group 258, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 34.  
Group 259, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 35.  
Group 260, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 36.  
Group 261, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 37.  
Group 262, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 38.

Art Unit: 1653

Group 263, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 39.

Group 264, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 41.

Group 265, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 42.

Group 266, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 43.

Group 267, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 44.

Group 268, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 45.

Group 269, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 46.

Group 270, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 47.

Group 271, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 48.

Group 272, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 50.

Group 273, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 51.

Group 274, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 52.

Group 275, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 54.

Group 276, claim(s) 18, drawn to method of treatment by administering polypeptide having SEQ ID NO: 54.

Group 277, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 1.

Group 278, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 2.

Group 279, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 3.

Group 280, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 4.

Group 281, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 5.

Group 282, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 6.

Group 283, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 7.

Group 284, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 10.

Group 285, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 11.

Art Unit: 1653

Group 286, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 12.

Group 287, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 13.

Group 288, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 14.

Group 289, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 15.

Group 290, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 17.

Group 291, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 18.

Group 292, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 20.

Group 293, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 22.

Group 294, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 23.

Group 295, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 24.

Group 296, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 25.

Group 297, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 26.

Group 298, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 28.

Group 299, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 29.

Group 300, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 30.

Group 301, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 31.

Group 302, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 32.

Group 303, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 33.

Group 304, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 34.

Group 305, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 35.

Group 306, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 36.

Group 307, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 37.

Group 308, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 38.

Group 309, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 39.

Group 310, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 41.

Art Unit: 1653

Group 311, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 42.

Group 312, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 43.

Group 313, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 44.

Group 314, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 45.

Group 315, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 46.

Group 316, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 47.

Group 317, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 48.

Group 318, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 50.

Group 319, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 51.

Group 320, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 52.

Group 321, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 53.

Group 322, claim(s) 19, drawn to a method of screening agonists of polypeptide having SEQ ID NO: 54.

Group 323, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 1.

Group 324, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 2.

Group 325, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 3.

Group 326, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 4.

Group 327, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 5.

Group 328, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 6.

Group 329, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 7.

Group 330, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 10.

Group 331, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 11.

Group 332, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 12.

Group 333, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 13.

Group 334, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 14.

Group 335, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 15.

Group 336, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 17.

Group 337, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 18.

Group 338, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 20.

Group 339, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 22.

Group 340, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 23.

Group 341, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 24.

Group 342, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 25.

Group 343, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 26.

Group 344, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 28.

Group 345, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 29.

Group 346, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 30.

Art Unit: 1653

Group 347, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 31.  
Group 348, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 32.  
Group 349, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 33.  
Group 350, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 34.  
Group 351, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 35.  
Group 352, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 36.  
Group 353, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 37.  
Group 354, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 38.  
Group 355, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 39.  
Group 356, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 41.  
Group 357, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 42.  
Group 358, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 43.  
Group 359, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 44.  
Group 360, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 45.  
Group 361, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 46.  
Group 362, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 47.  
Group 363, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 48.  
Group 364, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 50.  
Group 365, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 51.  
Group 366, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 52.  
Group 367, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 53.  
Group 368, claim(s) 20, drawn to an agonist of polypeptide having SEQ ID NO: 54.

Group 369, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 1.  
Group 370, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 2.  
Group 371, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 3.  
Group 372, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 4.  
Group 373, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 5.  
Group 374, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 6.  
Group 375, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 7.  
Group 376, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 10.  
Group 377, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 11.  
Group 378, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 12.  
Group 379, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 13.  
Group 380, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 14.  
Group 381, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 15.



Art Unit: 1653

Group 382, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 17.

Group 383, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 18.

Group 384, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 20.

Group 385, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 22.

Group 386, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 23.

Group 387, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 24.

Group 388, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 25.

Group 389, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 26.

Group 390, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 28.

Group 391, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 29.

Group 392, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 30.

Group 393, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 31.

Group 394, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 32.

Group 395, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 33.

Group 396, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 34.

Group 397, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 35.

Group 398, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 36.

Group 399, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 37.

Group 400, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 38.

Group 401, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 39.

Group 402, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 41.

Group 403, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 42.

Group 404, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 43.

Group 405, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 44.

Group 406, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 45.

Art Unit: 1653

Group 407, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 46.

Group 408, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 47.

Group 409, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 48.

Group 410, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 50.

Group 411, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 51.

Group 412, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 52.

Group 413, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 53.

Group 414, claim(s) 21, drawn to a method of treatment by administering the agonist of polypeptide having SEQ ID NO: 54.

Group 415, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 1.

Group 416, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 2.

Group 417, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 3.

Group 418, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 4.

Group 419, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 5.

Group 420, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 6.

Group 421, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 7.

Group 422, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 10.

Group 423, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 11.

Group 424 claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 12.

Group 425, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 13.

Group 426, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 14.

Group 427, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 15.

Group 428, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 17.

Group 429, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 18.

Group 430, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 20.

Art Unit: 1653

Group 431, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 22.

Group 432, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 23.

Group 433, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 24.

Group 434, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 25.

Group 435, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 26.

Group 436, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 28.

Group 437, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 29.

Group 438, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 30.

Group 439, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 31.

Group 440, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 32.

Group 441, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 33.

Group 442, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 34.

Group 443, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 35.

Group 444, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 36.

Group 445, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 37.

Group 446, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 38.

Group 447, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 39.

Group 448, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 41.

Group 449, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 42.

Group 450, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 43.

Group 451, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 44.

Group 452, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 45.

Group 453, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 46.

Group 454, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 47.

Group 455, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 48.

Art Unit: 1653

Group 456, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 50.

Group 457, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 51.

Group 458, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 52.

Group 459, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 53.

Group 460, claim(s) 22, drawn to a method of screening antagonists of polypeptide having SEQ ID NO: 54.

Group 461, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 1.

Group 462, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 2.

Group 463, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 3.

Group 464, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 4.

Group 465, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 5.

Group 466, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 6.

Group 467, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 7.

Group 468, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 10.

Group 469, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 11.

Group 470, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 12.

Group 471, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 13.

Group 472, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 14.

Group 473, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 15.

Group 474, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 17.

Group 475, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 18.

Group 476, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 20.

Group 477, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 22.

Group 478, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 23.

Group 479, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 24.

Group 480, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 25.

Group 481, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 26.

Group 482, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 28.

Group 483, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 29.

Group 484, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 30.

Group 485, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 31.

Group 486, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 32.

Group 487, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 33.

Group 488, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 34.

Group 489, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 35.

Group 490, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 36.

Group 491, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 37.

Group 492, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 38.

Group 493, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 39.

Group 494, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 41.

Group 495, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 42.

Group 496, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 43.

Group 497, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 44.

Group 498, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 45.

Art Unit: 1653

Group 499, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 46.  
Group 500, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 47.  
Group 501, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 48.  
Group 502, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 50.  
Group 503, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 51.  
Group 504, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 52.  
Group 505, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 53.  
Group 506, claim(s) 23, drawn to an antagonist of polypeptide having SEQ ID NO: 54.

Group 507, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 1.  
Group 508, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 2.  
Group 509, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 3.  
Group 510, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 4.  
Group 511, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 5.  
Group 512, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 6.  
Group 513, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 7.  
Group 514, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 10.  
Group 515, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 11.  
Group 516, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 12.  
Group 517, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 13.  
Group 518, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 14.  
Group 519, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 15.  
Group 520, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 17.  
Group 521, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 18.  
Group 522, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 20.  
Group 523, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 22.  
Group 524, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 23.  
Group 525, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 24.  
Group 526, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 25.

Art Unit: 1653

Group 527, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 26.

Group 528, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 28.

Group 529, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 29.

Group 530, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 30.

Group 531, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 31.

Group 532, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 32.

Group 533, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 33.

Group 534, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 34.

Group 535, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 35.

Group 536, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 36.

Group 537, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 37.

Group 538, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 38.

Group 539, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 39.

Group 540, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 41.

Group 541, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 42.

Group 542, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 43.

Group 543, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 44.

Group 544, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 45.

Group 545, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 46.

Group 546, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 47.

Group 547, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 48.

Group 548, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 50.

Group 549, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 51.

Group 550, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 52.

Group 551, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 53.

Art Unit: 1653

Group 552, claim(s) 24, drawn to a method of treatment by administering the antagonist of polypeptide having SEQ ID NO: 54.

Group 553, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 1.

Group 554, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 2.

Group 555, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 3.

Group 556, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 4.

Group 557, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 5.

Group 558, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 6.

Group 559, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 7.

Group 560, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 10.

Group 561, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 11.

Group 562, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 12.

Group 563, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 13.

Group 564, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 14.

Group 565, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 15.

Group 566, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 17.

Group 567, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 18.

Group 568, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 20.

Group 569, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 22.

Group 570, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 23.

Group 571, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 24.

Group 572, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 25.

Group 573, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 26.

Group 574, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 28.

Group 575, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 29.

Art Unit: 1653

Group 576, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 30.

Group 577, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 31.

Group 578, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 32.

Group 579, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 33.

Group 580, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 34.

Group 581, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 35.

Group 582, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 36.

Group 583, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 37.

Group 584, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 38.

Group 585, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 39.

Group 586, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 41.

Group 587, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 42.

Group 588, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 43.

Group 589, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 44.

Group 590, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 45.

Group 591, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 46.

Group 592, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 47.

Group 593, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 48.

Group 594, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 50.

Group 595, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 51.

Group 596, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 52.

Group 597, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 53.

Group 598, claim(s) 25, drawn to a method for screening compounds that bind to polypeptide having SEQ ID NO: 54.

Group 599, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 1.



Art Unit: 1653

Group 600, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 2.  
Group 601, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 3.  
Group 602, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 4.  
Group 603, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 5.  
Group 604, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 6.  
Group 605, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 7.  
Group 606, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 10.  
Group 607, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 11.  
Group 608, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 12.  
Group 609, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 13.  
Group 610, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 14.  
Group 611, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 15.  
Group 612, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 17.  
Group 613, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 18.  
Group 614, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 20.  
Group 615, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 22.  
Group 616, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 23.  
Group 617, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 24.  
Group 618, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 25.  
Group 619, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 26.  
Group 620, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 28.  
Group 621, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 29.  
Group 622, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 30.  
Group 623, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 31.  
Group 624, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 32.

Art Unit: 1653

Group 625, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 33.

Group 626, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 34.

Group 627, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 35.

Group 628, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 36.

Group 629, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 37.

Group 630, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 38.

Group 631, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 39.

Group 632, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 41.

Group 633, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 42.

Group 634, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 43.

Group 635, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 44.

Group 636, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 45.

Group 637, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 46.

Group 638, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 47.

Group 639, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 48.

Group 640, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 50.

Group 641, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 51.

Group 642, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 52.

Group 643, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 53.

Group 644, claim(s) 26, drawn to a method for screening compounds that modulate the activity of polypeptide having SEQ ID NO: 54.

Group 645, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 1.

Group 646, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 2.

Group 647, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 3.



Art Unit: 1653

Group 673, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 35.

Group 674, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 36.

Group 675, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 37.

Group 676, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 38.

Group 677, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 39.

Group 678, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 41.

Group 679, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 42.

Group 680, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 43.

Group 681, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 44.

Group 682, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 45.

Group 683, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 46.

Group 684, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 47.

Group 685, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 48.

Group 686, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 50.

Group 687, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 51.

Group 688, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 52.

Group 689, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 53.

Group 690, claim(s) 27 and 29, drawn to a method of screening for compounds that alter the expression of polynucleotide encoding polypeptide having SEQ ID NO: 54.

Group 691, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 1.

Group 692, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 2.

Group 693, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 3.

Group 694, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 4.

Group 695, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 5.

Group 696, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 6.

Art Unit: 1653

Group 697, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 7.

Group 698, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 10.

Group 699, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 11.

Group 700, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 12.

Group 701, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 13.

Group 702, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 14.

Group 703, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 15.

Group 704, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 17.

Group 705, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 18.

Group 706, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 20.

Group 707, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 22.

Group 708, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 23.

Group 709, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 24.

Group 710, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 25.

Group 711, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 26.

Group 712, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 28.

Group 713, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 29.

Group 714, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 30.

Group 715, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 31.

Group 716, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 32.

Group 717, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 33.

Group 718, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 34.

Group 719, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 35.

Group 720, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 36.

Group 721, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 37.

Art Unit: 1653

Group 722, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 38.

Group 723, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 39.

Group 724, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 41.

Group 725, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 42.

Group 726, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 43.

Group 727, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 44.

Group 728, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 45.

Group 729, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 46.

Group 730, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 47.

Group 731, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 48.

Group 732, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 50.

Group 733, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 51.

Group 734, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 52.

Group 735, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 53.

Group 736, claim(s) 28, drawn to a method for assessing toxicity using a polynucleotide encoding polypeptide having SEQ ID NO: 54.

The inventions listed as Groups 1-736 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The sequences presented in Claim 1, for example, do not share a common structure or a common function. Table 2 (page 81) of the specification shows that SEQ ID NO: 2 is homologous to a proliferating cell nucleolar antigen p120. In contrast, SEQ ID NO: 3 is homologous to a tumor suppressor p33ING1. SEQ ID NO: 4 is homologous to a germ cell-less protein. See all of Table 2. Therefore, Groups 2-46, lacks the same or corresponding special technical feature of Group 1, drawn to the polypeptide having SEQ ID NO: 1.

Art Unit: 1653


Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 703-308-0034. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 703-308-2329. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

\*\*\*



KAREN COCHRANE CARLSON, PH.D  
PRIMARY EXAMINER